A Phase Ib Study of PDR001 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Trial Profile

A Phase Ib Study of PDR001 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs PDR 001 (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 13 Jun 2017 Planned primary completion date changed from 18 Jul 2019 to 30 Dec 2018.
    • 24 Apr 2017 Planned End Date changed from 4 Jul 2019 to 18 Jul 2019.
    • 24 Apr 2017 Planned primary completion date changed from 4 Jul 2019 to 18 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top